Abbott Q3 results top estimates, keeps 2026 EPS forecast unchanged (ABT:NYSE)
Abbott Laboratories reported Q3 non-GAAP EPS of $1.42, exceeding estimates by $0.01. Revenue grew 14.4% year-over-year to $13.01B, beating expectations by $20M. The company maintained its FY2026 adjusted diluted EPS guidance of $5.50–$5.55, which is in line with consensus.
How this was made
The 30-second read
Why it matters
The earnings beat and steady guidance suggest continued operational stability but limited growth catalyst.
Market read
The report provides fresh earnings data for a large‑cap health stock, offering a short‑term trading opportunity.
What to watch
Potential headwinds in Abbott's diagnostics segment not reflected in the brief release.
Background
Abbott Laboratories is a diversified healthcare company with pharmaceuticals, diagnostics, and nutrition businesses.
Ticker impact
Abbott reported Q3 Non‑GAAP EPS $1.42 beating estimates and reaffirmed FY2026 EPS guidance $5.50‑$5.55.
likely modest upside as market prices in the beat and steady outlook
The beat is small ($0.01) but the guidance remains unchanged, supporting a limited positive reaction.
Market effects
Healthcare sector may see slight lift from a large‑cap earnings beat.
U.S. markets may experience modest positive bias in pharma stocks.
Limited global impact beyond U.S. healthcare equities.
Counterpoint
Investors could view the unchanged guidance as a warning sign despite the beat.
Key entities
- CompanyAbbott Laboratories
U.S. healthcare conglomerate reporting Q3 results.